(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model New preliminary clinical results show Annamycin ...

Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to Venetoclax. Recent preclinical studies and preliminary ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company, has announced an amendment to its clinical trial protocol for the Phase 3 "MIRACLE" study of Annamycin in ...

On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment ...

Looking forward, Moleculin Biotech is preparing for a Phase 3 trial for its lead program, Annamycin, while seeking additional funding to support ongoing operations and clinical trials. Management ...